DUBLIN, Feb. 4, 2016 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/x2r6d5/global_viral) has announced the addition of the "Global Viral Partnering 2010-2016: Deal trends, players and financials" company profile to their offering.
Global Viral Partnering 2010 to 2016 provides the full collection of Viral disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Viral disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Viral deals.
The report presents financial deal terms values for Viral deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Viral dealmaking trends.
Global Viral Partnering 2010 to 2016 includes:
- Trends in Viral dealmaking in the biopharma industry since 2010
- Analysis of Viral deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Viral deal contract documents
- Comprehensive access to over 3500 Viral deal records
- The leading Viral deals by value since 2010
- Most active Viral dealmakers since 2010
In Global Viral Partnering 2010 to 2016, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Viral dealmaking
Chapter 3 - Financial deal terms for Viral partnering
Chapter 4 - Leading Viral deals and dealmakers
Chapter 5 - Viral contract document directory
Chapter 6 - Viral dealmaking by therapeutic target
For more information visit
Laura Wood, +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets